Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

17.08 +0.05 (+0.29%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid... 
Via Benzinga
The Generic Drugs Antitrust Case
Imagine that in the market for generic drugs, a group of companies form a cartel to raise prices on the products controlled by their group. What pattern might you expect to see for the prices of... 
Via Talk Markets
8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Via Benzinga
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
Drug Maker Organon Stock Scores Relative Strength Upgrade
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. 
Via Investor's Business Daily
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock
Via Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000?
Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000. 
Via InvestorPlace
Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock
Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning. 
Via InvestorPlace
TEVA Stock Pops 4% as Teva Receives FDA Approval
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar. 
Via InvestorPlace
Exposures Product Safety
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. 
Via Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Teva Pharmaceutical Industries Limited
Via Business Wire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report
Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs. 
Via Benzinga
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. 
Via Benzinga
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Exposures US Equities
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
TEVA earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates
Teva Pharmaceutical surpasses Q4 2023 sales expectations, reporting $4.46 billion. Teva plans to divest API business for revenue optimization. Outlook for FY 2024. 
Via Benzinga
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. 
Via Investor's Business Daily
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Teva Reports Growth in Fourth Quarter and Full Year 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.